LG Electronics Launches 5MP Diagnostic Monitor for Breast Imaging

Addition of 21.3-inch High-Definition Mammography Monitor Helps Accelerate LG’s B2B Medical Device Business Growth

LG Electronics (LG) is accelerating its B2B medical device business, expanding its lineup of diagnostic monitors with the new 21HQ613D-B, which was recently cleared by the U.S. Food and Drug Administration for sale in the U.S.

Intended for digital mammography and digital breast tomosynthesis, the 21HQ613D-B is a 21.3-inch 5-megapixel (MP) IPS diagnostic monitor designed to deliver high-definition radiological images and maintains consistent image quality through its internal front calibration sensor and calibration software.

The 21HQ613D-B offers exceptional definition and brightness. Its LG IPS display provides a resolution of 2,048 x 2,560, a luminance of 1100cd/m² and a contrast ratio of 1800:1. Suitable for reviewing various types of medical images, including breast MRIs, CT scans and ultrasound, the diagnostic monitor features an internal front sensor that removes the need for an external calibration device. With LG Calibration Studio medical software, users can conveniently conduct DICOM calibration and quality assurance tests that comply with international quality control standards for medical monitors.

The 21HQ613D-B also incorporates helpful features to assist users in the close examination of medical images, such as Focus View Mode. Controllable with either a mouse or keyboard, Focus View Mode lets users focus in on a specific part of an image, dimming the rest of the screen in order to highlight the selected area. Additionally, Multi-Resolution Mode (5, 3 and 2MP) makes it possible to quickly adjust screen resolution to suit the type of image being viewed.

For a more productive and organized workspace, this diagnostic monitor supports daisy-chaining via DisplayPort connection. An easy and efficient way of linking monitors, daisy-chaining helps reduce desk clutter and simplify cable management. LG’s new 5MP diagnostic monitor also offers a comfortable user experience thanks to an ergonomic stand with adjustable tilt, height, swivel and bi-directional pivoting functionality.

The diagnostic monitor’s five hotkeys improve user convenience by providing a quick and simple way to adjust settings or switch between modes. Meanwhile, the Presence Sensor helps to conserve energy, automatically shutting off the display if no motion has been detected for five minutes. The Down Light and Wall Light features enable users to read documents when the room is dim or completely dark, the former illuminating the desk or table surface below the monitor and the latter casting light on the area behind it. For a better viewing experience, the Auto Luminance Sensor automatically adjusts screen brightness according to ambient conditions.

LG’s expanded lineup of diagnostic monitors covers the major display needs of large hospitals. Along with the new 5MP model, the company provides 2MP and 3MP monitors – primarily used for reading radiological images – and 8MP and 12MP products equipped with PBP (Picture-by-picture) mode, which allows simultaneous review of multiple diagnostic images.

“LG’s new 5MP diagnostic monitor is tailored for reviewing mammograms and breast tomosynthesis, providing a high-quality medical imaging display with both simple management and practical features for users,” said Stephen K. Hu, LG Business Solutions USA’s head of medical displays. “We’re dedicated to providing cutting-edge solutions for the medical sector with our display technologies, and the addition of the latest 5MP monitor underscores this commitment to innovation.”

Key Specifications:

 

LG Diagnostic Monitor

(21HQ613D)

Display Panel Type IPS
Size 21.3-inch
Aspect Ratio 4:5
Resolution 5MP (2,048 x 2,560)
Color Gamut (Typ.) NTSC (CIE 1931) 72%
Brightness (Typ.) 1100cd/m²
Contrast Ratio (Typ.) 1800:1
Response Time

(Gray-To-Gray)

5ms (GtG)
Feature DICOM Compliant Yes
Hardware Calibration Yes
Display Mode Multi-Resolution Mode (5/3/2MP), Focus View Mode
Video Signals Input Terminals DisplayPort x2, DVI-D (Dual Link) x1
User
Convenience
Dual Controller Yes
Lighting Yes (Down / Wall)
Hot Key Yes (5 keys)
Presence Sensor Yes
Physical

Specifications

Adjustable Stand Pivot (Bi-Directional) / Swivel: ±15° / Tilt.: -5°~20° / Height Range: 110mm

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”